Exact Sciences Serves Investors Exactly What They Wished For

Diagnostic and cancer test products provider Exact Sciences Corp. NASDAQ: EXAS saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detection test Cologuard. This is a patient-friendly, non-invasive stool-based DNA test that users can be…#exactsciencescorp #exas #fit #fda #oncotypedx #exactsciences #myriadgeneticsinc #questdiagnosticsinc #dgx #eps
Source: Reuters: Health - Category: Consumer Health News Source Type: news